• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Imprimis Pharmaceuticals acquires Buderer intellectual property assets

Imprimis Pharmaceuticals acquires Buderer intellectual property assets

June 18, 2013
CenterWatch Staff

Imprimis Pharmaceuticals has acquired the intellectual property (IP) rights related to proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug, a compounding pharmacy member of PCCA.

The acquisition allows Imprimis to pursue the commercial development of these proprietary innovations and provides Imprimis with a right of first refusal on additional Buderer Drug intellectual property and drug development opportunities.

"This new relationship, which could lead to up to three new development programs, is a good example of our plan to begin to leverage our agreement with PCCA into proprietary IP that may ultimately lead to the FDA approval of new medicines to address unmet patient needs,” said Mark L. Baum, Imprimis chief executive officer.

"Imprimis understands that the ideas we generate come from a 'boots on the ground' approach—dealing directly with doctors and their patients to address specific and often unmet patient needs,” said Matt Buderer, R.Ph., vice president and chief compounding pharmacist with Buderer Drug. “We also appreciate that some drugs are demonstrably difficult for compounders to make and that often additional research and development is required before a drug can be used in humans, including more formal preclinical and clinical research.”

Compounding pharmacies work with physicians to develop medications for individual patients. Examples are alternative dosage strengths or unique dosage forms, such as topical creams or gels, suspensions or solutions with more tolerable drug delivery vehicles. Access to these formulations may be limited if patients don't live near a compounding pharmacy or cannot cover the out-of-pocket costs.

"Commercialization of formulations developed by Buderer Drug by taking them through a regulated FDA process would in the long run allow more patients to benefit from these medications,” said Baum. “At the same time, Imprimis respects the rights of pharmacists and physicians to continue to serve their patients' needs. Imprimis believes having an FDA-approved derivative of compounding's innovations will enhance the overall acceptance of compounding and develop new opportunities for compounders to serve patients."

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing